The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKanabo Grp Plc Regulatory News (KNB)

Share Price Information for Kanabo Grp Plc (KNB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.85
Bid: 1.70
Ask: 2.00
Change: 0.00 (0.00%)
Spread: 0.30 (17.647%)
Open: 1.85
High: 1.85
Low: 1.85
Prev. Close: 1.85
KNB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Materia Receives Licence for Malta Facility

14 Sep 2021 07:05

RNS Number : 6370L
Kanabo Group PLC
14 September 2021
 

14 September 2021

 

Kanabo Group Plc

 

("Kanabo" or "the Company")

 

Materia Receives Commercial Production Licence for Malta Facility

 

Kanabo Group Plc (LSE:KNB), a medical cannabis R&D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, notes the recent announcement published by Materia. Kanabo are delighted that Materia's wholly-owned subsidiary, Materia Malta Operating Ltd. ("Materia Malta"), has received its Licence for the Production of Cannabis for Medicinal and Research Purposes (the "Licence") from the Malta Medicines Authority.

 

The receipt of the Licence is the final requirement for Materia Malta to begin commercial production and export of medical cannabis for commercial purposes. Materia Malta, which is already EU GMP certified, has an annual throughput capacity of 6,000kg, representing a potential sale value of €36M based on a blended average sales price across several key European markets.

 

Materia Malta has now begun the process of importing its first batch of raw material for commercial production and will begin fulfillment of its supply commitments across Europe imminently, starting with the initial target markets of Germany, Malta and the UK. The first product has already been successfully registered on the narcotics licence of Materia Deutschland GmbH ahead of its import into and across Germany.

 

Kanabo CEO, Avihu Tamir said; "Materia's progress is remarkable. Subject to completion of the merger, the facility in Malta will enable Kanabo's enlarged group to broaden its distribution across Europe and solidify our plan for a complete supply and distribution line."

 

Deepak Anand, CEO of Materia, said; "We are delighted to be fully licensed and to begin generating revenues from our Malta facility. I'd like to congratulate our entire team for helping realise our vision of a state-of-the-art processing facility, especially in working through the difficult circumstances presented by the pandemic over the last 18 months."

 

"As happy as we are to secure our licence, we immediately begin execution on the next phase of our plan," commented Nick Pateras, Managing Director, Europe, at Materia. "We now have a fully built and licensed pathway into the European market for cultivation partners all over the world. This encompasses our in-house processing expertise in Malta on top of our distribution capabilities into and across Germany, Europe's biggest market, through Materia Deutschland."

 

Kurt Farruga, CEO of Malta Enterprise (the government's economic development agency), also commented; "We are delighted to see Materia achieve this milestone. We have been working closely with Materia since the beginning and the caliber of the team exemplifies the type of company we are proud to support here in Malta. We fully expect Materia to be one of the industry's long-term leaders."

 

The full announcement can be found on Materia's website (http://www.materia.global).

 

Further Details

In an announcement published on 26 July 2021, Kanabo announced the signing of a non-binding term sheet with Materia, to acquire Materia's European businesses (the "Proposed Transaction"), which includes Materia Malta. The closing of the Proposed Transaction remains subject to (among other items) due diligence, the entering into of a definitive agreement, the receipt of all requisite third-party approvals and the drafting and approval of a prospectus, as per the Listing Rules. The Company and Materia are currently undertaking the due diligence process and are working on reaching a definitive agreement.

 

The Proposed Transaction, if completed, would constitute a Reverse Take-over under the Listing Rules ("RTO"). Upon the successful completion of the RTO and publication of a prospectus, Kanabo anticipates that it would subsequently re-apply for listing on the Standard Segment of the Official List.

 

 

Kanabo Group Plc

 

Meirav Horn

Via Vox Markets

 

 

Peterhouse Capital Ltd

 

Eran Zucker / Guy Miller (Financial Adviser)

Tel: +44 (0)20 7469 0930

Lucy Williams / Charles Goodfellow (Corporate Broker)

Tel: +44 (0)20 7469 0930

 

 

Vox Markets (Investor Relations)

 

Kat Perez

KanaboGroup@voxmarkets.co.uk

 

 

About Kanabo Group Plc

Kanabo Group Plc is an R&D company currently selling a range of THC-Free Retail CBD Products in the Primary Markets and is in the process of developing further Medical Cannabis Products. The company's core strategy is to increase revenues from the sale of its Retail CBD Products in the wellness sector and to grow the Kanabo brand through its marketing initiatives.

 

 

Learn more here; https://www.voxmarkets.co.uk/listings/LON/KNB/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STREAENDFFXFEAA
Date   Source Headline
2nd Dec 20222:59 pmRNSResignation of Auditor
15th Nov 20227:30 amRNSUpdate re: Investment into Hellenic Dynamics
24th Oct 20227:00 amRNSKanabo appointed to BSI Steering Group Committee
30th Sep 20227:01 amRNSInvestor Webinar hosted by Vox Markets
30th Sep 20227:00 amRNSHalf-year Report
30th Aug 20222:37 pmRNSGrant of Options
19th Aug 20225:30 pmRNSAppointment of Auditor
17th Aug 20222:05 pmRNSSecond Price Monitoring Extn
17th Aug 20222:00 pmRNSPrice Monitoring Extension
3rd Aug 20229:05 amRNSSecond Price Monitoring Extn
3rd Aug 20229:00 amRNSPrice Monitoring Extension
30th Jun 20225:02 pmRNSResult of AGM
30th Jun 20223:29 pmRNSAGM Statement
16th Jun 20227:00 amRNSNew Subsidiary
9th Jun 20227:00 amRNSContract Extension
8th Jun 20221:00 pmRNSNotice of AGM
6th Jun 20227:00 amRNSFinal Results
20th May 20227:00 amRNSUpdate on the Acquisition of Materia
3rd May 20227:00 amRNSTotal Voting Rights
19th Apr 20223:00 pmRNSExercise of Options and Total Voting Rights
22nd Mar 20227:00 amRNSBoard Changes
11th Mar 202211:23 amRNSInvestor Updates
9th Mar 20227:00 amRNSMoU with Forbe Ltd
1st Mar 20222:05 pmRNSSecond Price Monitoring Extn
1st Mar 20222:00 pmRNSPrice Monitoring Extension
28th Feb 20222:00 pmRNSTotal Voting Rights
25th Feb 20227:00 amRNSDirector/PDMR Dealing
23rd Feb 20227:00 amRNSBlock listing Interim Review
22nd Feb 20229:05 amRNSSecond Price Monitoring Extn
22nd Feb 20229:00 amRNSPrice Monitoring Extension
22nd Feb 20227:00 amRNSCompany Webinar
21st Feb 20225:30 pmRNSExercise of Put Option
21st Feb 20225:15 pmRNSOversubscribed Placing to Raise £2.25m
21st Feb 20224:54 pmRNSAcquisition of GP Service Ltd
31st Jan 202211:00 amRNSTotal Voting Rights
18th Jan 20227:00 amRNSMateria Announces Trading Update for 4Q22
6th Jan 20224:41 pmRNSSecond Price Monitoring Extn
6th Jan 20224:36 pmRNSPrice Monitoring Extension
31st Dec 202111:41 amRNSTotal Voting Rights
31st Dec 202110:00 amRNSGrant of Options
30th Dec 20211:00 pmRNSAchievement of Milestones
16th Dec 20217:05 amRNSMateria Malta First Sales in Europe
15th Dec 20217:00 amRNSPatent Advancement
7th Dec 20217:00 amRNSSubmission for Bioavailability and Efficacy Trial
6th Dec 20213:45 pmRNSExercise of Options
6th Dec 20217:00 amRNSUK Moves to License e-cigarettes and vaporizers
30th Nov 20214:02 pmRNSTotal Voting Rights
29th Nov 202111:05 amRNSSecond Price Monitoring Extn
29th Nov 202111:00 amRNSPrice Monitoring Extension
26th Nov 202111:57 amRNSKanabo to present at Mello: 29 November 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.